vs
Side-by-side financial comparison of Dianthus Therapeutics, Inc. (DNTH) and Pasithea Therapeutics Corp. (KTTA). Click either name above to swap in a different company.
Dianthus Therapeutics, Inc. is the larger business by last-quarter revenue ($284.0K vs $240.7K, roughly 1.2× Pasithea Therapeutics Corp.). Pasithea Therapeutics Corp. runs the higher net margin — -2126.1% vs -22687.3%, a 20561.3% gap on every dollar of revenue. Pasithea Therapeutics Corp. produced more free cash flow last quarter ($-4.5M vs $-47.1M).
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
Pasithea Therapeutics Corp. is a clinical-stage biopharmaceutical firm dedicated to developing novel treatments for psychiatric and neurological conditions including treatment-resistant mood disorders. It primarily operates in North American and European markets, targeting patient segments that lack effective existing treatment options.
DNTH vs KTTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2022
| Metric | | |
|---|---|---|
| Revenue | $284.0K | $240.7K |
| Net Profit | $-64.4M | $-5.1M |
| Gross Margin | — | — |
| Operating Margin | -24486.3% | -1679.5% |
| Net Margin | -22687.3% | -2126.1% |
| Revenue YoY | -78.6% | — |
| Net Profit YoY | -126.6% | — |
| EPS (diluted) | $-1.53 | $-1.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0K | — | ||
| Q3 25 | $396.0K | — | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $1.9M | — | ||
| Q1 24 | $874.0K | — | ||
| Q3 23 | $924.0K | — |
| Q4 25 | $-64.4M | — | ||
| Q3 25 | $-36.8M | — | ||
| Q1 25 | $-29.5M | — | ||
| Q4 24 | $-28.4M | — | ||
| Q3 24 | $-25.2M | — | ||
| Q2 24 | $-17.6M | — | ||
| Q1 24 | $-13.7M | — | ||
| Q3 23 | $-14.8M | — |
| Q4 25 | -24486.3% | — | ||
| Q3 25 | -10173.7% | — | ||
| Q1 25 | -2852.7% | — | ||
| Q4 24 | -2406.9% | — | ||
| Q3 24 | -1376.6% | — | ||
| Q2 24 | -1191.8% | — | ||
| Q1 24 | -2041.6% | — | ||
| Q3 23 | -1705.5% | — |
| Q4 25 | -22687.3% | — | ||
| Q3 25 | -9284.1% | — | ||
| Q1 25 | -2537.5% | — | ||
| Q4 24 | -2144.8% | — | ||
| Q3 24 | -1159.0% | — | ||
| Q2 24 | -945.1% | — | ||
| Q1 24 | -1573.0% | — | ||
| Q3 23 | -1597.7% | — |
| Q4 25 | $-1.53 | — | ||
| Q3 25 | $-0.97 | — | ||
| Q1 25 | $-0.82 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.74 | — | ||
| Q2 24 | $-0.51 | — | ||
| Q1 24 | $-0.54 | — | ||
| Q3 23 | $-3.78 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $404.3M | $33.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $493.4M | $42.5M |
| Total Assets | $530.9M | $45.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $404.3M | — | ||
| Q3 25 | $402.6M | — | ||
| Q1 25 | $263.2M | — | ||
| Q4 24 | $275.2M | — | ||
| Q3 24 | $281.1M | — | ||
| Q2 24 | $360.7M | — | ||
| Q1 24 | $377.0M | — | ||
| Q3 23 | $189.9M | — |
| Q4 25 | $493.4M | — | ||
| Q3 25 | $546.5M | — | ||
| Q1 25 | $328.6M | — | ||
| Q4 24 | $352.5M | — | ||
| Q3 24 | $337.9M | — | ||
| Q2 24 | $358.2M | — | ||
| Q1 24 | $372.7M | — | ||
| Q3 23 | $178.4M | — |
| Q4 25 | $530.9M | — | ||
| Q3 25 | $577.4M | — | ||
| Q1 25 | $348.6M | — | ||
| Q4 24 | $374.0M | — | ||
| Q3 24 | $354.2M | — | ||
| Q2 24 | $369.0M | — | ||
| Q1 24 | $382.5M | — | ||
| Q3 23 | $192.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-47.0M | $-4.4M |
| Free Cash FlowOCF − Capex | $-47.1M | $-4.5M |
| FCF MarginFCF / Revenue | -16591.9% | -1874.2% |
| Capex IntensityCapex / Revenue | 48.6% | 38.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-132.8M | $-14.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-47.0M | — | ||
| Q3 25 | $-30.6M | — | ||
| Q1 25 | $-27.6M | — | ||
| Q4 24 | $-27.4M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-14.5M | — | ||
| Q1 24 | $-14.9M | — | ||
| Q3 23 | $-10.0M | — |
| Q4 25 | $-47.1M | — | ||
| Q3 25 | $-30.6M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-27.5M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-14.5M | — | ||
| Q1 24 | $-15.0M | — | ||
| Q3 23 | $-10.1M | — |
| Q4 25 | -16591.9% | — | ||
| Q3 25 | -7717.2% | — | ||
| Q1 25 | -2377.8% | — | ||
| Q4 24 | -2072.0% | — | ||
| Q3 24 | -980.3% | — | ||
| Q2 24 | -780.7% | — | ||
| Q1 24 | -1713.2% | — | ||
| Q3 23 | -1088.4% | — |
| Q4 25 | 48.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 3.7% | — | ||
| Q3 23 | 7.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
